https://www.selleckchem.com/pr....oducts/abtl-0812.htm
BACKGROUND Domains encompassing emotional disorders in relapsing-remitting MS (RRMS) patients are still unclear. METHODS We performed a 24-month, multicenter, single-arm, prospective study. RRMS patients started IFN-β treatment at baseline. The primary endpoint was lack of emotional control, measured using the "Echelle d'HumeurDépressive" (EHD) scale three times at baseline and at 10 post-treatment visits. Secondary endpoints were emotional blunting, irritability, fatigue, depression and anxiety. A linear mixed covariance model assess
Like
Comment
Share
